featured
IASLC WCLC Virtual: KEYNOTE-042 Demonstrates Continued Benefits for First-Line Pembrolizumab in Non-Small Cell Lung Cancer
Improvements over chemotherapy were observed for overall survival and second progression-free survival
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.